Real IntelligenceReviewIndependent Clinical Evaluation
Back to Atlas

Diagnostic imaging

Rapid LVO

RapidAI

Analyzes CT angiography to triage and notify clinicians of suspected large vessel occlusion.

Designed for

Stroke team and radiologist

Care setting

Hospital

Specialty

Neuroradiology, Stroke care

Public evidence assessedReviewed August 31, 2026

Our assessment

Bottom line

Rapid LVO has a credible regulated evidence base for detecting and triaging suspected large vessel occlusion. Public evidence does not eliminate the need to understand current-version performance, false alerts, and actual treatment-time effects in each adopting stroke network.

Based on public sources. RIR did not independently test this product. This is not an endorsement or recommendation.

What the evidence supports

Reviewed sources establish a cleared product for computer-assisted LVO triage and notification.

What remains uncertain

Current-version performance, local workflow effects, and transportability across scanners and populations require site-specific review.

How it was studied

Rapid LVO has FDA 510(k) records and reported retrospective, blinded, multicenter and multinational testing against expert-adjudicated CTA findings. The represented Atlas record does not yet establish performance of the exact version at a specific hospital.

Product facts

Intended use
Support prioritization and notification for suspected LVO findings on eligible CT angiography studies.
Represented version
FDA-cleared device family; current deployed version requires confirmation
Regulatory context
Rapid LVO is represented by FDA 510(k) K221248. Exact deployed version and indications require confirmation.

Sources reviewed

2 public sources represented in this evidence profile.

FDA 510(k) record K221248RegulatoryRapid ischemic stroke solutionsOfficial product
For clinical and investment reviewEvidence context and questions for deeper review

Evidence source base

Regulatory and developer materials. Independent local replication and exact version matching remain necessary.

Important limitation

Dataset accuracy does not establish scanner transportability, false-alert burden, workflow adoption, treatment-time improvement, or outcome benefit at a local stroke network.

Questions to ask

  1. 01Which vessel locations are within the deployed indication?
  2. 02How is performance monitored after scanner changes?
  3. 03What is the local alert-to-intervention effect?
Return to AtlasHow RIR evaluates evidence